Oracle Health Sciences Translational Research Center enables pharmaceutical and biotech companies, contract research organizations, as well as academic research organizations to normalize, aggregate, and analyze data from numerous internal and external sources, including clinical systems, lab systems, next-generation sequencing platforms, and biobanks, to identify new predictive biomarkers, best practices for diagnosis and treatment, and more effective personalized therapies.
Oracle Health Sciences Omics Data Bank enables turnkey integration and analysis of multiple types of molecular data, including whole genome sequencing and gene expression data irrespective of the platform used. The omics data model provides researchers with unprecedented power and agility in analyzing large molecular data sets from internal and external sources.
The solution also includes out-of-the-box adapters for loading customer generated molecular profiling data, as well as public domain data from sources such as Ensembl, The Cancer Genome Atlas and Pathway Commons, to further speed time to value.
Oracle Health Sciences Translational Research Center scales to support large, global studies incorporating thousands of whole genome sequences while ensuring appropriate levels of security and access control.
Oracle Health Sciences Translational Research Center runs on Oracle Exadata Database Machine, delivering the extreme performance required for querying vast data sets.
"The release of Oracle Health Sciences Omics Data Bank for Oracle Health Sciences Translational Research Center demonstrates Oracle's continued commitment to making personalized medicine a reality," said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. "Molecular data is a critical component of any translational medicine initiative, and Oracle Health Sciences Translational Research Center now has the power to help researchers address the big data challenges associated with bioinformatics."
"With the rapidly dropping cost of whole genome sequencing, the challenge for personalized medicine is moving from generation of the data to analysis," said Dr. Brian Druker, M.D., director, Oregon Health & Science University Knight Cancer Institute. "Oracle Health Sciences Translational Research Center represents an important step forward."
"The Inova Translational Medicine Institute (ITMI) is in the midst of one of the largest genome sequencing projects ever," said Dr. John Niederhuber, Chief Executive Officer, Inova Translational Medicine Institute and former Director of the National Cancer Institute. "Our goal is to unlock new insights in pre-term delivery. We hope to identify genomic alternations that identify high risk patients early in their pregnancy, so that they may take advantage of therapies designed to delay pre-term delivery. Working with the outstanding NICU physicians and nurses at Inova Fairfax Hospital, ITMI anticipates that our research will enhance our understanding of the mechanisms that lead to pre-term delivery. Oracle is uniquely positioned to support the complete integration of our clinical data with data from the 1,500 whole genomes sequenced as a part of the project, providing us with the platform required to perform genomic analyses, leading to improved patient care through personalized genomic medicine."